Basic Stats
| CIK | 1642178 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Breathtec Biomedical Inc
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| December 21, 2022 |
RW 1 formrw.htm FORM RW December 21, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Dear Sirs/Mesdames: Re: Algernon Pharmaceuticals Inc. Request for Withdrawal of Registration Statement on Form F-1 Initially filed February 22, 2022 File No. 333-262878 Pursuant to Rule 477 promulgated |
|
| June 3, 2022 |
Form of Underwriting Agreement(2) COMMON SHARES, PRE-FUNDED WARRANTS AND COMMON WARRANTS OF ALGERNON PHARMACEUTICALS INC. |
|
| June 3, 2022 |
As filed with the U.S. Securities and Exchange Commission on June 2, 2022 As filed with the U.S. Securities and Exchange Commission on June 2, 2022 Registration No. 333-262878 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1/A (Amendment No. 6) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALGERNON PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia 2834 N/A (State or other jurisdiction o |
|
| June 3, 2022 |
Form of Warrant Certificate(2) COMMON SHARES PURCHASE WARRANT ALGERNON PHARMACEUTICALS INC. Warrant Shares: Initial Exercise Date: , 2022 THIS COMMON SHARES PURCHASE WARRANT (the "Warrant") certifies that, for value received, or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the "Initial Exercise |
|
| June 3, 2022 |
EX-FILING FEES 8 exhibitfilingfees.htm EXHIBIT107 Exhibit 107 Calculation of Filing Fee Tables FORM F-1 ………….. (Form Type) ALGERNON PHARMACEUTICALS INC. ……………………………………………………..… (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offer |
|
| May 10, 2022 |
FWP 1 formfwp.htm FORM FWP Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-262878 Relating to Preliminary Prospectus dated May 9, 2022 DISCLAIMER Certain statements in this presentation (the "Presentation") are forward-looking statements, which are made as of the date of this Presentation or as of the date of the effective date of information described in t |
|
| May 9, 2022 |
As filed with the U.S. Securities and Exchange Commission on May 9, 2022 As filed with the U.S. Securities and Exchange Commission on May 9, 2022 Registration No. 333-262878 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1/A (Amendment No. 5) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALGERNON PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia 2834 N/A (State or other jurisdiction of |
|
| May 9, 2022 |
EX-FILING FEES 3 exhibitfilingfees.htm EXHIBIT 107 Exhibit 107 Calculation of Filing Fee Tables FORM F-1 ………….. (Form Type) ALGERNON PHARMACEUTICALS INC. ……………………………………………………..… (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offe |
|
| April 25, 2022 |
Form of Warrant Agency Agreement(1) Algernon Pharmaceuticals Inc. and American Stock Transfer & Trust Company, LLC, as Warrant Agent Warrant Agency Agreement Dated as of , 2022 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2022 ("Agreement"), by and between Algernon Pharmaceuticals Inc., a British Columbia corporation (the "Company"), and American Stock Transfer & Trust Company, LLC, a New York limited liability t |
|
| April 25, 2022 |
Form of Compensation Warrant(1) REPRESENTATIVE COMMON SHARES PURCHASE WARRANT ALGERNON PHARMACEUTICALS INC. Warrant Shares: Initial Exercise Date: , 2022 THIS REPRESENTATIVE COMMON SHARES PURCHASE WARRANT (the "Warrant") certifies that, for value received, or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| April 25, 2022 |
Form of Underwriting Agreement(1) EX-1.1 2 exhibit1-1.htm EXHIBIT 1.1 COMMON SHARES, PRE-FUNDED WARRANTS AND COMMON WARRANTS OF ALGERNON PHARMACEUTICALS INC. UNDERWRITING AGREEMENT , 2022 Ladenburg Thalmann & Co. Inc. As the Representative of the Several underwriters, if any, named in Schedule I hereto 640 Fifth Avenue, 4th Floor New York, New York 10019 Ladies and Gentlemen: The undersigned, Algernon Pharmaceuticals Inc., a compa |
|
| April 25, 2022 |
EX-FILING FEES 12 exhibitfilingfees.htm EXHIBIT 107 Exhibit 107 Calculation of Filing Fee Tables FORM F-1 ………….. (Form Type) ALGERNON PHARMACEUTICALS INC. ……………………………………………………..… (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Off |
|
| April 25, 2022 | ||
| April 25, 2022 |
As filed with the U.S. Securities and Exchange Commission on April 22, 2022 F-1/A 1 formf1a.htm FORM F-1/A As filed with the U.S. Securities and Exchange Commission on April 22, 2022 Registration No. 333-262878 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1/A (Amendment No. 4) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALGERNON PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia 2834 N |
|
| April 25, 2022 |
Form of Pre-Funded Warrant Certificate(1) PRE-FUNDED COMMON SHARES PURCHASE WARRANT ALGERNON PHARMACEUTICALS INC. Warrant Shares: Initial Exercise Date: , 2022 THIS PRE-FUNDED COMMON SHARES PURCHASE WARRANT (the "Warrant") certifies that, for value received, or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof |
|
| April 25, 2022 |
Form of Warrant Certificate(1) COMMON SHARES PURCHASE WARRANT ALGERNON PHARMACEUTICALS INC. Warrant Shares: Initial Exercise Date: , 2022 THIS COMMON SHARES PURCHASE WARRANT (the "Warrant") certifies that, for value received, or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the "Initial Exercise |
|
| April 15, 2022 |
As filed with the U.S. Securities and Exchange Commission on April 14, 2022 F-1/A 1 formf1a.htm FORM F-1/A As filed with the U.S. Securities and Exchange Commission on April 14, 2022 Registration No. 333-262878 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1/A (Amendment No. 3) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALGERNON PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia 2834 N |
|
| April 6, 2022 |
As filed with the U.S. Securities and Exchange Commission on April 6, 2022 F-1/A 1 formf1a.htm FORM F-1/A As filed with the U.S. Securities and Exchange Commission on April 6, 2022 Registration No. 333-262878 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1/A (Amendment No. 2) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALGERNON PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia 2834 N/ |
|
| March 24, 2022 |
As filed with the U.S. Securities and Exchange Commission on March __, 2022 As filed with the U.S. Securities and Exchange Commission on March , 2022 Registration No. 333-262878 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1/A (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALGERNON PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia 2834 N/A (State or other jurisdiction o |
|
| March 24, 2022 |
Stock Option Plan dated September 11, 2015(1) BREATHTEC BIOMEDICAL, INC. (formerly, PBA Acquisitions Corp.) STOCK OPTION PLAN DATED FOR REFERENCE SEPTEMBER 11, 2015 Approved by the board of directors and shareholders on September 11, 2015. TABLE OF CONTENTS Page SECTION 1 DEFINITIONS AND INTERPRETATION 1 1.1 Definitions 1 1.2 Choice of Law 6 1.3 Headings 6 SECTION 2 GRANT OF OPTIONS 6 2.1 Grant of Options 6 2.2 Record of Option Grants 6 2.3 E |
|
| March 24, 2022 |
Restricted Share Unit Plan effective as of July 23, 2020, as amended November 12, 2021(1) ALGERNON PHARMACEUTICALS INC. RESTRICTED SHARE UNIT PLAN EFFECTIVE AS OF JULY 23, 2020, AS AMENDED NOVEMBER 12, 2021 TABLE OF CONTENTS ARTICLE 1 PURPOSE AND INTERPRETATION 1 Section 1.1 Purpose 1 Section 1.2 Definitions 1 Section 1.3 Interpretation 5 Section 1.4 Governing Law 5 Section 1.5 Severability 5 ARTICLE 2 SHARE CAPITAL 5 Section 2.1 Shares Reserved 5 ARTICLE 3 ADMINISTRATION 6 Section 3.1 |
|
| March 24, 2022 |
Number: BC1033065 BUSINESS CORPORATIONS ACT (British Columbia) ARTICLES of ALGERNON PHARMACEUTICALS INC. |
|
| February 22, 2022 |
Compensation Committee Charter (1) ALGERNON PHARMACEUTICALS INC. (the "Corporation") COMPENSATION COMMITTEE CHARTER Purpose The Compensation Committee (the "Committee") of the Board of Directors of the Corporation (the "Board of Directors") assists the Board of Directors in fulfilling its oversight responsibilities relating to officer and director compensation, succession planning for senior management, development and retention of |
|
| February 22, 2022 |
ALGERNON PHARMACEUTICALS INC. as the Corporation and AST TRUST COMPANY (CANADA) as the Warrant Agent WARRANT INDENTURE Providing for the Issue of Warrants Dated as of May 13, 2020 TABLE OF CONTENTS ARTICLE 1 ARTICLE 1 INTERPRETATION 6 Section 1.1 Definitions 6 Section 1.2 Gender and Number 11 Section 1.3 Headings, Etc 11 Section 1.4 Day not a Business Day. 11 Section 1.5 Time of the Essence. 11 Se |
|
| February 22, 2022 |
AGENCY AGREEMENT May 13, 2020 Algernon Pharmaceuticals Inc. Suite 915 - 700 West Pender Street Vancouver, BC V6C 1G8 Attention: Christopher Moreau, Chief Executive Officer Dear Sir: The undersigned, Mackie Research Capital Corporation (the "Agent"), understands that Algernon Pharmaceuticals Inc. (the "Company") proposes to create, offer, issue and sell up to 17,143,000 special warrants of the Comp |
|
| February 22, 2022 |
ALGERNON PHARMACEUTICALS INC. as the Corporation and AST TRUST COMPANY (CANADA) as the Warrant Agent WARRANT INDENTURE Providing for the Issue of Warrants Dated as of November 1, 2019 TABLE OF CONTENTS ARTICLE 1 INTERPRETATION 6 Section 1.1 Definitions 6 Section 1.2 Gender and Number 10 Section 1.3 Headings, Etc. 10 Section 1.4 Day not a Business Day 10 Section 1.5 Time of the Essence 10 Section 1 |
|
| February 22, 2022 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EXECUTIVE EMPLOYMENT AGREEMENT BETWEEN: ALGERNON PHARMACEUTICALS INC. |
|
| February 22, 2022 | ||
| February 22, 2022 |
EX-3.2 3 exhibit3-2.htm EXHIBIT 3.2 |
|
| February 22, 2022 |
EXECUTIVE EMPLOYMENT AGREEMENT BETWEEN: ALGERNON PHARMACEUTICALS INC., a company incorporated pursuant to the laws of the Province of British Columbia, with an office at 915-700 West Pender Street, Vancouver, British Columbia (the "Company") AND: CHRISTOPHER J. MOREAU, an individual resident in Winnipeg, Manitoba (the "Executive") (collectively the "Parties") WHEREAS: (A) The Company is engaged in |
|
| February 22, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-1 ????.. (Form Type) ALGERNON PHARMACEUTICALS INC. ????????????????????..? (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Pric |
|
| February 22, 2022 |
Nominating and Corporate Governance Committee Charter (1) ALGERNON PHARMACEUTICALS INC. (the "Corporation") NOMINATING AND CORPORATE GOVERNANCE COMMITTEE CHARTER Purpose The purpose of the Corporation's Nominating and Corporate Governance Committee (the "Committee") is to: (i) identify and recommend to the Board of Directors of the Corporation (the "Board of Directors") individuals qualified to be nominated for election to the Board of Directors; (ii) re |
|
| February 22, 2022 |
ALGERNON PHARMACEUTICALS INC. Special Warrant Indenture May 13, 2020 TABLE OF CONTENTS 1. INTERPRETATION 2 1.1 Definitions 2 1.2 Headings 6 1.3 Gender 6 1.4 Weekends and Holidays 6 1.5 Meaning of "Outstanding" 6 1.6 Time 7 1.7 Applicable Law 7 1.8 Severability 7 1.9 Currency 7 1.10 Conflicts 7 1.11 Schedules 7 2. ISSUE AND PURCHASE OF SPECIAL WARRANTS 7 2.1 Creation, Form and Terms of Special Warr |
|
| February 22, 2022 |
ALGERNON PHARMACEUTICALS INC. (the "Corporation") AUDIT COMMITTEE CHARTER Objectives The Corporation's Audit Committee (the "Audit Committee") will assist the Corporation's Board of Directors (the "Board of Directors") in fulfilling its oversight responsibilities for: 1. the system of internal control over financial reporting; 2. the audit process; 3. compliance with legal and regulatory requireme |
|
| February 22, 2022 |
Code of Business Conduct and Ethics (1) ALGERNON PHARMACEUTICALS INC. (the "Corporation") CODE OF BUSINESS CONDUCT AND ETHICS Objectives The Corporation's commitment to ethical and lawful business conduct is a fundamental shared value of our Board of Directors (the "Board of Directors"), management and employees and critical to our success. Our standards for business conduct provide that we will uphold ethical and legal standards vigoro |
|
| February 22, 2022 |
EX-21.1 15 exhibit21-1.htm EXHIBIT 21.1 Exhibit 21.1 SUBSIDIARIES OF ALGERNON PHARMACEUTICALS INC. The following is a list of all the subsidiaries of the Company and the corresponding jurisdiction of incorporation or organization of each. All subsidiaries of the Company are directly or indirectly owned by the Company. Name of Subsidiary Place of Incorporation/Formation Ownership Interest Nash Phar |
|
| February 22, 2022 |
Execution Version AGENCY AGREEMENT September 30, 2019 Algernon Pharmaceuticals Inc. |
|
| February 22, 2022 |
1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL SHARE EXCHANGE AGREEMENT THIS SHARE EXCHANGE AGREEMENT is made effective the 26th day of September, 2018. |
|
| February 22, 2022 |
As filed with the U.S. Securities and Exchange Commission on February __, 2022 F-1 1 formf1.htm FORM F-1 As filed with the U.S. Securities and Exchange Commission on February , 2022 Registration No. [●] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALGERNON PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia 2834 N/A (State or other jurisdiction |
|
| February 22, 2022 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL DARTMOUTH CONFIDENTIAL DARTMOUTH COLLEGE INTELLECTUAL PROPERTY LICENSE AGREEMENT This Intellectual Property License Agreement (this "Agreement") by and between the Trustees of Dartmouth College ("Dartmouth") with an address at 11 Rope Ferry Road, Hanover, New Hampshire 03755, and Algernon Pharmaceuticals, Inc. |
|
| February 22, 2022 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EXECUTIVE EMPLOYMENT AGREEMENT BETWEEN: ALGERNON PHARMACEUTICALS INC. |
|
| January 21, 2022 |
ALGERNON PHARMACEUTICALS INC. as the Corporation and AST TRUST COMPANY (CANADA) as the Warrant Agent WARRANT INDENTURE Providing for the Issue of Warrants Dated as of May 13, 2020 TABLE OF CONTENTS ARTICLE 1 ARTICLE 1 INTERPRETATION 6 Section 1.1 Definitions 6 Section 1.2 Gender and Number 11 Section 1.3 Headings, Etc 11 Section 1.4 Day not a Business Day. 11 Section 1.5 Time of the Essence. 11 Se |
|
| January 21, 2022 |
DRS/A 1 filename1.htm This Amendment No. 1 to Draft Registration Statement is confidentially submitted to the U.S. Securities and Exchange Commission pursuant to Section 106(a) of the Jumpstart Our Business Startups Act of 2012 on January 21, 2022 and is not being filed publicly under Securities Act of 1933, as amended. Registration No. [●] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washingt |
|
| January 21, 2022 |
EXECUTIVE EMPLOYMENT AGREEMENT EX-10.7 8 filename8.htm EXECUTIVE EMPLOYMENT AGREEMENT BETWEEN: ALGERNON PHARMACEUTICALS INC., a company incorporated pursuant to the laws of the Province of British Columbia, with an office at 915-700 West Pender Street, Vancouver, British Columbia (the "Company") AND: CHRISTOPHER J. MOREAU, an individual resident in Winnipeg, Manitoba (the "Executive") (collectively the "Parties") WHEREAS: (A) T |
|
| January 21, 2022 |
DARTMOUTH COLLEGE INTELLECTUAL PROPERTY LICENSE AGREEMENT CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL DARTMOUTH CONFIDENTIAL DARTMOUTH COLLEGE INTELLECTUAL PROPERTY LICENSE AGREEMENT This Intellectual Property License Agreement (this "Agreement") by and between the Trustees of Dartmouth College ("Dartmouth") with an address at 11 Rope Ferry Road, Hanover, New Hampshire 03755, and Algernon Pharmaceuticals, Inc. |
|
| January 21, 2022 |
AGENCY AGREEMENT May 13, 2020 Algernon Pharmaceuticals Inc. Suite 915 - 700 West Pender Street Vancouver, BC V6C 1G8 Attention: Christopher Moreau, Chief Executive Officer Dear Sir: The undersigned, Mackie Research Capital Corporation (the "Agent"), understands that Algernon Pharmaceuticals Inc. (the "Company") proposes to create, offer, issue and sell up to 17,143,000 special warrants of the Comp |
|
| January 21, 2022 |
EXECUTIVE EMPLOYMENT AGREEMENT CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EXECUTIVE EMPLOYMENT AGREEMENT BETWEEN: ALGERNON PHARMACEUTICALS INC. |
|
| January 21, 2022 |
EXECUTIVE EMPLOYMENT AGREEMENT CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EXECUTIVE EMPLOYMENT AGREEMENT BETWEEN: ALGERNON PHARMACEUTICALS INC. |
|
| January 21, 2022 |
EX-10.2 3 filename3.htm Execution Version AGENCY AGREEMENT September 30, 2019 Algernon Pharmaceuticals Inc. Suite 915 - 700 West Pender Street Vancouver, BC V6C 1G8 Attention: Christopher Moreau, Chief Executive Officer Dear Sir: Algernon Pharmaceuticals Inc. (the "Company") hereby engages Mackie Research Capital Corporation (the "Agent") to act as its exclusive agent to offer and sell on a commer |
|
| January 21, 2022 |
1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL SHARE EXCHANGE AGREEMENT THIS SHARE EXCHANGE AGREEMENT is made effective the 26th day of September, 2018. |
|
| January 21, 2022 |
ALGERNON PHARMACEUTICALS INC. Special Warrant Indenture May 13, 2020 TABLE OF CONTENTS ALGERNON PHARMACEUTICALS INC. Special Warrant Indenture May 13, 2020 TABLE OF CONTENTS 1. INTERPRETATION 2 1.1 Definitions 2 1.2 Headings 6 1.3 Gender 6 1.4 Weekends and Holidays 6 1.5 Meaning of "Outstanding" 6 1.6 Time 7 1.7 Applicable Law 7 1.8 Severability 7 1.9 Currency 7 1.10 Conflicts 7 1.11 Schedules 7 2. ISSUE AND PURCHASE OF SPECIAL WARRANTS 7 2.1 Creation, Form and Terms of Special Warr |
|
| January 21, 2022 |
ALGERNON PHARMACEUTICALS INC. as the Corporation and AST TRUST COMPANY (CANADA) as the Warrant Agent WARRANT INDENTURE Providing for the Issue of Warrants Dated as of November 1, 2019 TABLE OF CONTENTS ARTICLE 1 INTERPRETATION 6 Section 1.1 Definitions 6 Section 1.2 Gender and Number 10 Section 1.3 Headings, Etc. 10 Section 1.4 Day not a Business Day 10 Section 1.5 Time of the Essence 10 Section 1 |
|
| October 20, 2021 |
SECURITIES ELIGIBLE FOR FUTURE SALE DRS 1 filename1.htm This Draft Registration Statement is confidentially submitted to the U.S. Securities and Exchange Commission pursuant to Section 106(a) of the Jumpstart Our Business Startups Act of 2012 on October 19, 2021 and is not being filed publicly under Securities Act of 1933, as amended. Registration No. [●] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F |
|
| October 20, 2021 |
ALGERNON PHARMACEUTICALS INC. (the "Corporation") COMPENSATION COMMITTEE CHARTER ALGERNON PHARMACEUTICALS INC. (the "Corporation") COMPENSATION COMMITTEE CHARTER Purpose The Compensation Committee (the "Committee") of the Board of Directors of the Corporation (the "Board of Directors") assists the Board of Directors in fulfilling its oversight responsibilities relating to officer and director compensation, succession planning for senior management, development and retention of |
|
| October 20, 2021 |
ALGERNON PHARMACEUTICALS INC. (the "Corporation") CODE OF BUSINESS CONDUCT AND ETHICS ALGERNON PHARMACEUTICALS INC. (the "Corporation") CODE OF BUSINESS CONDUCT AND ETHICS Objectives The Corporation's commitment to ethical and lawful business conduct is a fundamental shared value of our Board of Directors (the "Board of Directors"), management and employees and critical to our success. Our standards for business conduct provide that we will uphold ethical and legal standards vigoro |
|
| October 20, 2021 |
ALGERNON PHARMACEUTICALS INC. (the "Corporation") NOMINATING AND CORPORATE GOVERNANCE COMMITTEE CHARTER Purpose The purpose of the Corporation's Nominating and Corporate Governance Committee (the "Committee") is to: (i) identify and recommend to the Board of Directors of the Corporation (the "Board of Directors") individuals qualified to be nominated for election to the Board of Directors; (ii) re |
|
| October 20, 2021 |
ALGERNON PHARMACEUTICALS INC. (the "Corporation") AUDIT COMMITTEE CHARTER EX-99.2 6 filename6.htm ALGERNON PHARMACEUTICALS INC. (the "Corporation") AUDIT COMMITTEE CHARTER Objectives The Corporation's Audit Committee (the "Audit Committee") will assist the Corporation's Board of Directors (the "Board of Directors") in fulfilling its oversight responsibilities for: 1. the system of internal control over financial reporting; 2. the audit process; 3. compliance with legal |
|
| October 20, 2021 | ||
| October 20, 2021 | ||
| October 20, 2021 |
EX-99.1 5 filename5.htm October 19, 2021 United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. USA 20549 Re: Algernon Pharmaceuticals Inc. - Registration Statement on Form F-1 Representation under Item 8.A.4 of Form 20-F ("Item 8.A.4") Algernon Pharmaceuticals Inc., a company incorporated pursuant to the laws of the Province of British Columbia, Canada (the "Company" |
